| 29-Oct-2024 | D | Outcome of Meeting
The Board has recommended Special Interim dividend of Rs. 12/- (120%) per equity share on face value of Rs.10 each of the Company. | 07-Nov-2024 | |
| 17-May-2024 | D | The Board has recommended a dividend of Rs. 32/- per equity share on face value of Rs.10 each for the year ended 31st March 2024, subject to approval of members at 99th Annual General Meeting. | 31-May-2024 | |
| 17-May-2023 | D | Board has recommended a dividend of Rs. 32/- per equity share on face value of Rs.10
each for the year ended 31 st March 2023, subject to approval of members at 98th Annual General Meeting. | 30-Jun-2023 | |
| 16-May-2022 | D | Board approved:
1. Dividend
The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022. | 07-Jul-2022 | |
| 16-May-2022 | D | Board approved:
1. Dividend
The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31 st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31 st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022. | 07-Jul-2022 | |
| 18-May-2021 | D | The Board has recommended a dividend of Rs. 30/- per equity share on face value of Rs.10 each for the year ended 31st March 2021, subject to approval of members at 96th Annual General Meeting. | 19-Jul-2021 | |
| 18-May-2020 | D | The Board has approved the Audited Financial Statements (Standalone and Consolidated) for the year ended 31st March 2020, Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2020 and further the Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 each which includes a special dividend of Rs. 20 per share for this year. (Year ended 31st March 2019 Rs.20 per share). | 17-Jul-2020 | |
| 18-May-2020 | D | The Board has approved the Audited Financial Statements (Standalone and Consolidated) for the year ended 31st March 2020, Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2020 and further the Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 each which includes a special dividend of Rs. 20 per share for this year. (Year ended 31st March 2019 Rs.20 per share). | 17-Jul-2020 | |
| 20-May-2019 | D | The Board has recommended a dividend of Rs. 20/- per equity share on face value of Rs. 10 each for the year ended 31st March 2019. The dividend if approved by the shareholders will be paid on or after 22nd July 2019. | 11-Jul-2019 | |
| 24-May-2018 | D | we are pleased to furnish the following information:
1. Dividend
The Board has recommended a dividend of Rs. 35/- per equity share on face value of Rs. 10 each for the year ended 31st March 2018. The dividend if approved by the shareholders will be paid after 24th July 2018 | 13-Jul-2018 | |
| 19-May-2017 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2017, inter alia, has recommended a dividend of 300% on the Equity Share capital i.e. Rs. 30/- per equity share for the year ended March 31, 2017. The dividend if approved by the shareholders will be paid after July 25, 2017. | 14-Jul-2017 | |
| 25-May-2016 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2016, inter alia, has transacted the following :
1. The Board has recommended a dividend of 500% on the Equity Share capital i.e. Rs. 50/- per equity share for the year ended March 31, 2016. The dividend if approved by the shareholders will be paid on or after July 28, 2016. | 15-Jul-2016 | |
| 18-May-2015 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2015, inter alia, has recommended a dividend of Rs. 62.50 per equity share for the fifteen month period ended March 31, 2015. The dividend if approved by the shareholders will be paid on or after August 01, 2015. | 23-Jul-2015 | |
| 18-Feb-2014 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2014, inter alia, have recommended the payment of a Dividend of Rs. 50/- per equity share for the year ended December 31, 2013. | 03-Apr-2014 | |
| 19-Feb-2013 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 19, 2013, inter alia, has recommended a Dividend of Rs. 50 per equity shares (Previous year : Rs. 45 per equity share). | 04-Apr-2013 | |
| 16-Feb-2012 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 16, 2012, inter alia, recommended a dividend of Rs. 45/- per equity share for the year ended December 31, 2011. | 29-Mar-2012 | |
| 14-Feb-2011 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2011, inter alia, recommends a dividend of Rs. 40/- per equity share for the year ended December 31, 2010. | 14-Mar-2011 | |
| 15-Feb-2010 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 15, 2010, inter alia, has recommended a Dividend of Rs. 30 per equity share (Previous year Rs. 22 per equity share and a special additional Dividend of Rs. 18 per equity share). | 10-Mar-2010 | |
| 18-Feb-2009 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2009, inter alia, has recommended the payment of a Dividend of Rs 22/- per equity share (Previous year Rs 18 per equity share) and a special additional Dividend of Rs 18 per equity share (Previous year Rs 18 per equity share).
Sc Code - 600660
(As Per BSE Bulletin dated on 18.02.2009) | 18-Mar-2009 | |
| 18-Feb-2009 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 18, 2009, inter alia, has recommended the payment of a Dividend of Rs 22/- per equity share (Previous year Rs 18 per equity share) and a special additional Dividend of Rs 18 per equity share (Previous year Rs 18 per equity share).
Sc Code - 600660
(As Per BSE Bulletin dated on 18.02.2009) | 18-Mar-2009 | |
| 22-Feb-2008 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 22, 2008, inter alia, has recommended the payment of a Dividend of Rs 18/- per equity share for the year ended December 31, 2007 and the Directors also recommend a special additional dividend of Rs 18/- per equity share. | 02-Apr-2008 | |
| 22-Feb-2008 | D | GlaxoSmithKline Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 22, 2008, inter alia, has recommended the payment of a Dividend of Rs 18/- per equity share for the year ended December 31, 2007 and the Directors also recommend a special additional dividend of Rs 18/- per equity share. | 02-Apr-2008 | |
| 16-Feb-2007 | D | 170% Final Dividend | 14-Mar-2007 | |
| 16-Feb-2007 | D | 140% Special Additional Dividend | 14-Mar-2007 | |
| 06-Sep-2018 | B | Trading Members of the Exchange are hereby informed that, GlaxoSmithKline Pharmaceuticals Limited has fixed the record date for the purpose of Bonus Issue. The transactions in the equity shares of the company would be on an ex-bonus basis with effect from the under mentioned date.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
GlaxoSmithKline Pharmaceuticals Limited
(500660)
RECORD DATE
13/09/2018
PURPOSE
Issue of 01 (One) Bonus equity share of Rs.10/- each for every 01 (One) existing equity share of Rs.10/- each held.
Ex-Bonus basis from Date & Sett. No.
11/09/2018 DR-116/2018-2019
Trading Members of the Exchange are requested to take of it. | 13-Sep-2018 | 1:1 |
| 29-Oct-2024 | BC | Outcome of Meeting
The Board has recommended Special Interim dividend of Rs. 12/- (120%) per equity share on face value of Rs.10 each of the Company. | 31-Mar-2025 | |
| 24-Oct-2024 | BC | Interim Dividend
Rs.12.0000 per share(120%)Special Interim Dividend
(As Per BSE Bulletin dated on 29.10.2024) | 07-Nov-2024 | |
| 30-Oct-2024 | BC | 120% Interim Dividend | 07-Nov-2024 | |
| 24-Oct-2024 | BC | GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve Unaudited Financial Result | 29-Oct-2024 | |
| 17-Jul-2024 | BC | GLAXOSMITHKLINE PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve Un-Audited Financial Resul | 02-Aug-2024 | |